Erik Faber MD PhD
fabermdphd.bsky.social
Erik Faber MD PhD
@fabermdphd.bsky.social
Onc fellow @mskcancercenter.bsky.social | #medchem 💊 PhD | aspiring #GIOnc doc | 🐶 dad | ex-HS teacher 🧑‍🏫 | @oslerresidency.bsky.social @umnmedchem.bsky.social‬ @dartmouthartsci.bsky.social alum | 🏳️‍🌈 he/him | #mdphd #doubledocs
Love this kind of work that connects conformational selectivity of a drug to its target with possibly improved therapeutic properties #medchem

www.nature.com/articles/s41...
GTP release-selective agonists prolong opioid analgesic efficacy - Nature
Mu opioid receptor agonists with a preference for the non-GTP-bound state of the G protein promote GTP release, thereby potentiating antinociceptive effects of drugs such as morphine and fentanyl with...
www.nature.com
February 7, 2026 at 8:15 PM
Still wild to me that #EKG findings could be informative for liver disease/ #cirrhosis - must be so much granular data in EKG tracings that we underappreciate

www.nature.com/articles/s41...
Detection of undiagnosed liver cirrhosis via AI-enabled electrocardiogram: a pragmatic, cluster-randomized clinical trial - Nature Medicine
In a trial involving 45 clinics and 15,596 visits, the use of an AI-based screening tool applied to ECG for opportunistic detection of advanced chronic liver disease led to a significant increase in n...
www.nature.com
January 24, 2026 at 3:01 PM
Nice review of state of #PDAC models: www.nature.com/articles/d41...
Client Challenge
www.nature.com
January 10, 2026 at 5:00 PM
Glad to see folks are working on this incredibly relevant clinical problem of #CIPN - more funding for this kind of work, please!

pubs.acs.org/doi/10.1021/...
pubs.acs.org
January 3, 2026 at 2:18 PM
A rare and impt dataset for #PDAC to analyze both primary + met lesions. Most meaningful may be the matched specimens, considering interpatient variability. E.g. the myCAF trend for the matched was the opposite of that from the composite analysis...

aacrjournals.org/cancerres/ar...
High-Dimensional Protein Analysis Uncovers Distinct Immunological and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma
Abstract. Pancreatic ductal adenocarcinoma (PDAC) is an aggressive tumor type with poor patient outcomes. Most patients present with metastatic disease, which generally has reduced immune infiltration...
aacrjournals.org
December 28, 2025 at 2:43 PM
Thought this review on clinical uses of CBD/THC was nicely done - balancing potential benefits (likely modest at best, strength of evidence is wanting) with some of the oft ignored potential risks, including some like increased CV disease I was unaware of

jamanetwork.com/journals/jam...
Therapeutic Use of Cannabis and Cannabinoids
This review discusses current evidence about the therapeutic use of cannabis and cannabinoids in adults, potential harms, and evidence-based clinical guidance, including pretreatment screening and add...
jamanetwork.com
December 20, 2025 at 2:18 PM
Nice review of #CCA, especially these outlined research priorities: 1) investigation into modulating the TME to expand therapeutic targets and 2) assessing if patient-derived 3D models can be used to tailor therapeutic approaches

www.nature.com/articles/s41...
Cholangiocarcinoma 2026: status quo, unmet needs and priorities - Nature Reviews Gastroenterology & Hepatology
In this Consensus Statement, an international panel of experts present an overview of the latest developments in the field of cholangiocarcinoma. A set of consensus recommendations and research priori...
www.nature.com
December 14, 2025 at 12:46 PM
A nice review on #cooperativity in #kinases - I think exploiting these properties may be the way we can forgo some of the tox that is dose limiting in the clinic associated with kinase inhibitors #medchem

www.sciencedirect.com/science/arti...
Allosteric binding cooperativity in kinases signaling, signalopathies, and drug development
Protein kinases catalyze the transfer of phosphate groups from ATP to specific substrates, initiating, modulating, or terminating signaling cascades. …
www.sciencedirect.com
December 7, 2025 at 7:23 PM
Always intriguing to find differences between drug response in 2D v. 3D models. Here, more drugs are efficacious in 3D - a bit counterintuitive since translation of efficacy from preclinical work relying on 2D models is historically poor... #medchem

www.sciencedirect.com/science/arti...
Drug screening in 3D microtumors reveals DDR1/2-MAPK12-GLI1 as a vulnerability in cancer-associated fibroblasts
Interactions between cancer cells and surrounding stromal cells are critical for tumor biology and treatment response. We compare drug screening resul…
www.sciencedirect.com
November 29, 2025 at 7:24 PM
If all models are wrong, will #organoids prove to be the most useful? A nice review of how we can take next steps to better assess clinical efficacy of drugs in a preclinical setting #medchem www.nature.com/articles/s41...
Human organoids as 3D in vitro platforms for drug discovery: opportunities and challenges - Nature Reviews Drug Discovery
Human organoids provide physiologically relevant, 3D models for studying disease mechanisms, drug efficacy and toxicity. This Review examines organoid generation methods, applications in preclinical d...
www.nature.com
November 17, 2025 at 2:54 AM
Age-old dilemma: HCO3 for AKI and met acidosis - Ya or Na? Still not life saving (need to reverse underlying etiology?) but less renal replacement needed

jamanetwork.com/journals/jam...
Sodium Bicarbonate for Severe Metabolic Acidemia and Acute Kidney Injury
This randomized clinical trial examines whether sodium bicarbonate infusion decreases day 90 all-cause mortality for patients with severe metabolic acidosis and moderate to severe acute kidney injury.
jamanetwork.com
November 9, 2025 at 1:22 AM
Impt for all of us ordering #ctDNA in #CRC: ctDNA-guided was NOT NON-inferior. Incredibly 1/2 ctDNA+ pts were escalated to FOLFOXIRI certainly w/o benefit - clearly we need better salvage treatments too

pubmed.ncbi.nlm.nih.gov/41115959/
Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial - PubMed
Adjuvant chemotherapy in stage III colon cancer provides uncertain benefit at the individual level. Circulating tumor DNA (ctDNA) may help refine risk-adjusted treatment selection. In this multicenter, randomized, phase 2/3 trial, patients with stage III colon cancer underwent ctDNA testing 5-6 week …
pubmed.ncbi.nlm.nih.gov
November 1, 2025 at 8:11 PM
I love a good #peptide inhibitor story, but given the expected poor #PK properties in the extended figures, I'd be willing to bet there's a small molecule-like metabolite driving most of this activity. Otherwise I worry there's something off-target #medchem

www.nature.com/articles/s41...
Targeting G1–S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors - Nature
Dual cyclin A/B RxL inhibitors selectively kill small cell lung cancer cells and other cancer cells with high E2F activity.
www.nature.com
October 25, 2025 at 6:51 PM
Such a great classic #medchem story. Going after these atypical targets (e.g. phosphoinositide/lipid/carbohydrate engagers) with creative biological validation is what patients need to experience better outcomes.

pubs.acs.org/doi/full/10....
Discovery, Optimization, and Anticancer Activity of Lipid-Competitive Pleckstrin Homology Domain-Containing Family A Inhibitors
Phosphoinositide signaling is a major cellular mechanism controlling cancer cell viability, proliferation, and survival. Yet, inhibition of lipid kinases that produce oncogenic phosphoinositides has a...
pubs.acs.org
October 18, 2025 at 7:40 PM
Cool translational work about an important health topic. Another example of how physician scientists and chemists can collaborate to move the needle forward #medchem #mdphd #doubledocs

pubmed.ncbi.nlm.nih.gov/40864684/
Resolving fibrosis by stimulating HSC-dependent extracellular matrix degradation - PubMed
Tissue fibrosis arises from a critical imbalance between the production and breakdown of extracellular matrix (ECM) components. Whereas current strategies predominantly focus on curbing ECM production...
pubmed.ncbi.nlm.nih.gov
October 4, 2025 at 1:15 PM
Two new #CDK2 papers bringing me back to my PhD days (1/2):

www.embopress.org/doi/full/10....

More mechanistic studies of CDK2/Spy1 role in meiosis including impt SUN1 phos site. Still unclear if CDK2/Spy1 is most impt for scaffolding/localization or enzymatic activity, or, "por que no los dos?"
Speedy A governs non-homologous XY chromosome desynapsis as a unique prerequisite for XY loop-axis organization | The EMBO Journal
imageimageIn mouse spermatocytes, the X and Y chromosomes undergo rapid non-homologous synapsis and desynapsis during early pachynema. This study reveals that X-Y desynapsis initiated by the atypical ...
www.embopress.org
September 27, 2025 at 3:09 PM
So...are there new cutoffs for AM cortisol that I shouldn't cort stim folks? Why the change?

jamanetwork.com/journals/jam...
Adrenal Insufficiency in Adults: A Review
This Review summarizes the pathophysiology of adrenal insufficiency and approaches to diagnosis, treatment, and prevention of adrenal crisis.
jamanetwork.com
September 12, 2025 at 11:46 PM
Provocative work - should we be dosing some drugs differently in patients with less bowel then? #medchem #PK

pubs.acs.org/doi/10.1021/...
Property-Based Prediction Uncovers Intestinal Excretion as an Elimination Route of Small-Molecule Drugs
Hepatic and renal pathways are traditionally considered the primary routes of drug clearance. However, emerging evidence highlights the significant role of direct intestinal excretion of unchanged drugs and metabolites. Intestinal excretion is often unrecognized due to complications arising from unabsorbed drugs and direct biliary excretion. Consequently, the extent and mechanisms of intestinal excretion remain systematically underexplored. Using bile duct cannulated rats, we investigated intestinal excretion for a library of drugs and proposed a predicative decision tree based on molecular descriptors. Mechanistically, passive permeability and efflux transporters emerged as key drivers of intestinal excretion in rats. We also demonstrated that modulating a single functional group can alter the clearance pathways between intestinal and biliary excretion. The insights into intestinal excretion as a major clearance pathway for metabolically stable small-molecule drugs provide a more comprehensive understanding for drug clearance and offer new considerations for drug design and pharmacokinetic assessment.
pubs.acs.org
August 30, 2025 at 9:35 PM
Interesting survey with lots of #mdphd #doubledocs representation. Sad observations:
- vast majority have changed career plans based on federal changes
- supportive environment = $ - even for those new to this career can see this

www.nature.com/articles/s41...
Perspectives of biomedical trainees during a time of policy disruption - Nature Medicine
Nature Medicine - Perspectives of biomedical trainees during a time of policy disruption
www.nature.com
August 24, 2025 at 11:35 PM
Reposted by Erik Faber MD PhD
Tying a drug candidate structure around into a macrocycle is real work: so why bother doing for things like kinase inhibitors?
When Do You Need a Macrocycle, Anyway?
www.science.org
August 22, 2025 at 4:53 PM
Reposted by Erik Faber MD PhD
85% of all drug candidates that go into human trials fail. Expensively. This is the central fact of the entire research pharma industry.
Ok folks: what is your favorite fact that you share with people (maybe a bit too) eagerly?
August 20, 2025 at 1:18 PM
Always exciting to see the next frontier of KRASi - and seemingly to never underestimate the power of a water H-bond network. Would be nice to see what happens when they optimize the PK and if they're able to retain this potency #medchem #kras

pubmed.ncbi.nlm.nih.gov/40780213/
A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers - PubMed
KRAS remains a challenging therapeutic target with limited effective inhibitors currently available. Here, we report the discovery of MCB-294, a potent dual-state pan-KRAS inhibitor capable of binding...
pubmed.ncbi.nlm.nih.gov
August 16, 2025 at 7:23 PM